MedPath

SANWA KAGAKU KENKYUSHO CO., LTD.

SANWA KAGAKU KENKYUSHO CO., LTD. logo
🇯🇵Japan
Ownership
Subsidiary
Established
1953-01-01
Employees
-
Market Cap
-
Website
http://www.skk-net.com

Clinical Trials

63

Active:2
Completed:32

Trial Phases

3 Phases

Phase 1:9
Phase 2:9
Phase 3:37

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (57 trials with phase data)• Click on a phase to view related trials

Phase 3
37 (64.9%)
Phase 1
9 (15.8%)
Phase 2
9 (15.8%)
phase_2_3
2 (3.5%)

Phase 3 Study of SK-1403

Phase 3
Completed
Conditions
Secondary Hyperparathyroidism
Interventions
Drug: Placebo
First Posted Date
2019-01-14
Last Posted Date
2020-03-09
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
153
Registration Number
NCT03801980
Locations
🇯🇵

Investigational site (there may be other sites in this country), Tokyo, Japan

SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Phase 3
Completed
Conditions
Secondary Hyperparathyroidism
Interventions
First Posted Date
2018-08-13
Last Posted Date
2020-03-09
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
157
Registration Number
NCT03626948
Locations
🇯🇵

Investigational site (there may be other sites in this country), Tokyo, Japan

Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism

Phase 2
Completed
Conditions
Secondary Hyperparathyroidism
Interventions
Drug: Dose-adjusted SK-1403
First Posted Date
2017-07-21
Last Posted Date
2019-03-15
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
58
Registration Number
NCT03226171
Locations
🇯🇵

Investigational site (there may be other sites in this country), Tokyo, Japan

A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus

Phase 2
Completed
Conditions
Uremic Pruritus in Hemodialysis Patients
Interventions
Drug: SK-1405 low dose
Drug: Placebo
Drug: SK-1405 high dose
First Posted Date
2017-07-14
Last Posted Date
2019-03-08
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
269
Registration Number
NCT03218501
Locations
🇯🇵

Investigational site (there may be other sites in this country), Tokyo, Japan

Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Phase 2
Completed
Conditions
Nocturia Due to Nocturnal Polyuria
Interventions
Drug: Placebo
First Posted Date
2017-04-14
Last Posted Date
2018-04-13
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Target Recruit Count
125
Registration Number
NCT03116191
Locations
🇯🇵

Investigational site (there may be other sites in this country), Tokyo, Japan

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.